 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...3334353637383940414243...123124» |
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma. (On Demand | Hall A; Poster Bd # 40) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3824;
P2
Further investigation into the biology mediating ICI-resistance and development of novel approaches to augment the efficacy of immune-based therapies in ACC are needed. (Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided lenvatinib and pembrolizumab for the study.) Clinical trial information: NCT04209660.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma. (On Demand | S404; Poster Bd # 451) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2858;
P2
In the LMS cohort, there were no responses, and PFS was poor. Enrollment to cohorts B and C is ongoing.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma. (On Demand | S406; Poster Bd # 277) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2593;
P2
The preliminary data has shown promising pathologic response with increased CD8+ T cell infiltration, supporting further investigation of neoadjuvant treatment in MM. Acknowledgement: Investigational funding and products are granted from Merck Sharp & Dohme LLC.
- Keytruda (pembrolizumab) / Merck (MSD), Kimmtrak (tebentafusp) / Immunocore, Lenvima (lenvatinib) / Eisai, Merck (MSD)
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp. (On Demand | Hall A; Poster Bd # 365b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2586;
P2
Biospecimens (longitudinal blood samples and tumor tissue at inclusion) will be collected during the study to allow biomarker research. Clinical trial information: NCT05282901.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, IBI110 / Innovent Biologics, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study. (On Demand | Hall A; Poster Bd # 419) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2345;
P1a
This combination therapy need to be further explored in this population. Clinical trial information: NCT04085185.
- A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer. (On Demand | Hall A; Poster Bd # 315b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2269;
P2
Safety analysis at the time of 36 patients enrolled did not demonstrate any new safety signals and the study was approved to continue enrollment. Clinical trial information: NCT03660826.
- Inlyta (axitinib) / Pfizer, Bavencio (avelumab) / EMD Serono
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair (On Demand | Hall A; Poster Bd # 315a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2268;
P2
With 8 confirmed PRs and 10 PFS6 responses, the co-primary endpoints were met and the combination of avelumab/axitinib is considered worthy of further study in this population of MMR-P EC. Clinical trial information: NCT02912572.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer. (On Demand | Hall A; Poster Bd # 310b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2259;
P2
The trial is open with 10 patients enrolled at the time of submission. Clinical trial information: NCT05114421.
- Herceptin (trastuzumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes. (On Demand | Hall A; Poster Bd # 297) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2242;
CVD management will become increasingly important with the use of targeted therapies including lenvatinib and trastuzumab. Our study highlights an additional area of disparity and suggests possible interventions.
- COM701 / Compugen, BMS-986207 / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer. (On Demand | Hall A; Poster Bd # 290) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2235;
P1/2
The triplet combination has a favorable safety/tolerability profile. Additional data analyses and pt follow up are ongoing and will be presented at the conference.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (Live Stream | Hall D1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2137;
P3
Additional data analyses and pt follow up are ongoing and will be presented at the conference. Treatment-na
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study. (On Demand | E450; Poster Bd # 10) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2131;
P2
These data support the use of lenva + pembro as first-line treatment for pts with non-clear cell RCC, regardless of histology. Clinical trial information: NCT04704219.
- Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study. (On Demand | Hall A; Poster Bd # 45) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2054;
P1b/2
Safety findings were consistent with individual profiles of each agent. The combination is being further evaluated in the phase 3 LITESPARK-011 study.
- NMS-153 / Nerviano Medical Sciences
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy. (Available On Demand; Poster Bd # 499a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1309;
P1/2
In HCC lines, specifically, NMS-01940153E showed ~2-Log higher anti-proliferative activity compared to sorafenib, lenvatinib, and regorafenib. Recruitment is currently ongoing in Italy and Spain and an FDA
- Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals. (Available On Demand; Poster Bd # 436) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1242;
Global trials may be appropriate to support drug approvals for HCC; however, to ensure results are applicable to US patients, sponsors should select sites that represent a similar population with respect to racial/ethnic representation, disease etiology, and treatment patterns. >1Trial 1 SHARP (sorafenib); Trial 2 RESORCE (regorafenib); Trial 3 REFLECT (lenvatinib); Trial 4 CELESTIAL (cabozantinib); Trial 5 REACH-2 (ramucirumab); Trial 6 IMbrave150 (atezolizumab/bevacizumab); Trial 7 HIMALAYA (durvalumab/tremelimumab).
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial. (Available On Demand; Poster Bd # 432) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1238;
P1
1, and Child-pugh grade A or B. Enrolled patients received TACE treatment (loplatin + raltitrexed + iodine oil) followed by TIS (200 mg, IV, on Day 1 of a 21-day cycle) and LEN (body weight ? 60 kg: 12 mg/day;
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma. (Available On Demand; Poster Bd # 424) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1230;
Data are in line with literature and correlates clinically. Prospective data are needed to fully incorporate EVA-PCD testing into the clinic.
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. (Available On Demand; Poster Bd # 400) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1207;
It can effectively control tumor progression and provide opportunities for resection with acceptable safety, which will bring great benefits to uHCC. Clinical trial information: ChiCTR2000039508.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT. (Available On Demand; Poster Bd # 399) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1206;
P3
This post hoc analysis, along with the results of the primary analysis of REFLECT [Kudo 2018, Lancet], demonstrates the efficacy of LEN regardless of etiology in uHCC, and supports LEN as a standard of care option for pts with 1L uHCC. Treatment efficacy by etiology should be assessed prospectively in future uHCC trials.
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma. (Available On Demand; Poster Bd # 397) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1204;
NGL was well tolerated and provided excellent disease control to patients with few options. Prospective trials are needed.
- E7386 / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A phase 1b study of E7386, a CREB-binding protein (CBP)/?-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma. (Available On Demand; Poster Bd # 396) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1203;
P1b
The combination showed promising activity in patients with HCC, including those pretreated with lenvatinib. Clinical trial information: NCT04008797.
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study. (Available On Demand; Poster Bd # 393) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1200;
Future large-scale randomised trials are warranted. Clinical trial information: ChiCTR2100050410.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy. (Available On Demand; Poster Bd # 363) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1171;
P2
Clinical trial information: ChiCTR2100050410. Lenvatinib combined with pembrolizumab was well tolerated, responses were seen, but the study did not meet the primary endpoint in ICI na
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC (clinicaltrials.gov) - Apr 26, 2023
P2, N=23, Not yet recruiting, Sponsor: Shenyang Tenth People's Hospital
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Management of hypertension during Lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm. (Pubmed Central) - Apr 25, 2023
HTN is a frequent and early adverse event in patients on LEN treatment. We suggest a diagnostic-therapeutic algorithm to be applied in clinical practice to allow efficient HTN control and improve patient compliance, reducing LEN discontinuation.
- ||| erfonrilimab (KN046) / Alphamab
Trial termination, Metastases: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent (clinicaltrials.gov) - Apr 25, 2023
P2/3, N=16, Terminated, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
We suggest a diagnostic-therapeutic algorithm to be applied in clinical practice to allow efficient HTN control and improve patient compliance, reducing LEN discontinuation. Suspended --> Terminated; Because the efficacy data did not meet expectations, the sponsor decided to terminate the study.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases: LEAP-003 China Extension: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study (clinicaltrials.gov) - Apr 25, 2023
P3, N=69, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Suspended --> Terminated; Because the efficacy data did not meet expectations, the sponsor decided to terminate the study. N=130 --> 69
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy. (Pubmed Central) - Apr 24, 2023
In contrast, L-carnitine had no influence on either lenvatinib-induced inhibition of vascular endothelial growth factor receptor 2 phosphorylation in human umbilical vein endothelial cells or angiogenesis in endothelial tube formation and mouse aortic ring assays. These results suggest that L-carnitine supplementation could prevent lenvatinib-induced muscle toxicity without diminishing its antineoplastic activity, although further clinical studies are needed to validate these findings.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: LEAP-003 China Extension: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study (clinicaltrials.gov) - Apr 24, 2023
P3, N=130, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
These results suggest that L-carnitine supplementation could prevent lenvatinib-induced muscle toxicity without diminishing its antineoplastic activity, although further clinical studies are needed to validate these findings. Trial primary completion date: Nov 2024 --> Jan 2023
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) (clinicaltrials.gov) - Apr 24, 2023
P3, N=660, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Nov 2024 --> Jan 2023 Trial primary completion date: Apr 2024 --> Jan 2023
- onCARlytics (CF33-CD19) / Imugene
Effective Combination Immunotherapy Using onCARlytics and Artemis (Board No. 586) - Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1215;
Currently, there are six systemic therapies available for patients with advanced disease including atezolizumab in combination with bevacizumab, lenvatinib, regorafenib, cabozantinib and ramucirumab while curative treatments include ablation, surgical resection, and liver transplantation...We have harnessed this capability of OV and developed a chimeric vaccinia-based OV called CF33-CD19t (onCARlytics) that delivers a non-signaling, truncated CD19 (CD19t) antigen to solid tumors allowing CD19-specific T cells to target them...In addition, this combination approach demonstrated impressive in vivo anti-tumor responses in a human xenograft HepG2 tumor model. By using this combination OV and CAR T cell strategy, we have now broadened the utility of CD19 ARTEMIS
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma (clinicaltrials.gov) - Apr 21, 2023
P3, N=80, Not yet recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- |||| livmoniplimab (ABBV-151) / AbbVie, budigalimab (ABBV-181) / AbbVie
New P2 trial, Adverse events, Checkpoint inhibition: LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 21, 2023
P2, N=120, Not yet recruiting, Sponsor: AbbVie
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Oncorine (recombinant human adenovirus type 5) / Mergen Ltd., Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Oncolytic virus, Metastases: Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) (clinicaltrials.gov) - Apr 21, 2023
P2, N=25, Not yet recruiting, Sponsor: Fudan University
- | Yutuo (zimberelimab) / Arcus Biosci, Gilead, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Checkpoint inhibition, Metastases: Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer (clinicaltrials.gov) - Apr 21, 2023
P2, N=33, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (clinicaltrials.gov) - Apr 21, 2023
P2, N=32, Not yet recruiting, Sponsor: Sun Yat-sen University
- A case report of a FGFR activation and genetic variability in metastatic sinonasal mucosal melanoma () - Apr 19, 2023 - Abstract #EADO2023EADO_443;
By using this combination OV and CAR T cell strategy, we have now broadened the utility of CD19 ARTEMIS A switch to second-line Lenvatinib and Pembrolizumab followed due to progressive disease...According to these results, we have received approval to start Erdafitinib (Balversa
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The prime time for management of hepatocellular carcinoma in Hong Kong. (Pubmed Central) - Apr 19, 2023
A switch to second-line Lenvatinib and Pembrolizumab followed due to progressive disease...According to these results, we have received approval to start Erdafitinib (Balversa No abstract available
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Metastases: Lenvatinib Plus #Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 https://t.co/b4lfhdoWTX (Twitter) - Apr 19, 2023
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases (clinicaltrials.gov) - Apr 18, 2023
P2, N=104, Recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2025
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: KEYMAKER-U03B: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B) (clinicaltrials.gov) - Apr 18, 2023
P1b/2, N=370, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2025 Trial completion date: May 2025 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: NeoLeap-HCC: Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 18, 2023
P2, N=43, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Trial completion date: May 2025 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025 Not yet recruiting --> Recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor (clinicaltrials.gov) - Apr 18, 2023
P2, N=120, Recruiting, Sponsor: National University Hospital, Singapore
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation. (Pubmed Central) - Apr 18, 2023
silencing not only enhanced the anticancer effects of combined lenvatinib and hypoxia, but also prevented the loss of effectiveness caused by bafilomycin A1, highlighting the potential role of HIF-1?-derived hypoxia response in the adaptive cellular response to lenvatinib and promoting resistance acquisition by autophagy modulation. Overall, NRP1 may constitute a potential therapeutic target to prevent lenvatinib failure derived from a hypoxia-associated modulation of autophagy in advanced HCC.
- || Review, Journal, Metastases: Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. (Pubmed Central) - Apr 17, 2023
P2
A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity. Many other combination treatments, such as pembrolizumab plus lenvatinib plus belzutifan (NCT04976634), are being investigated, possibly leading to more options in the first-line setting in the future.
- || Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. (Pubmed Central) - Apr 17, 2023
P3
Considering the unmet need for effective and tolerable treatment of advanced RCC following immune checkpoint inhibitors, belzutifan plus lenvatinib may have a positive benefit/risk profile. Clinical Trial Registration: NCT04586231 (ClinicalTrials.gov).
- Optimising first-line treatment in RAI-R-DTC () - Apr 14, 2023 - Abstract #WCTC2023WCTC_257;
Clinical Trial Registration: NCT04586231 (ClinicalTrials.gov). Sponsored by Eisai
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Agnostic Lenvatinib as well as General Issues for Invasive Disease such as Visceral Tracheal Esophageal Laryngeal Vascular and Nerve Invasion (Kocher Hall) - Apr 14, 2023 - Abstract #WCTC2023WCTC_128;
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P3 data, Metastases: #Lenvatinib & #Pembrolizumab in Previously Treated Advanced #Endometrialcancer: Updated Efficacy and Safety From the Randomized #Phase III Study 309/#KEYNOTE-775. In @JCO_ASCO #gyncsm @Lenvima_HCP @KEYTRUDA #clinicaltrial #Immunotherapy (Twitter) - Apr 14, 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Combination therapy, Metastases: Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma. (Pubmed Central) - Apr 14, 2023
This combination should be routinely offered to patients following progression or recurrence of systemic platinum and taxane chemotherapy. Although this regimen is safe and effective, clinicians should be aware of the known toxicities and assess patients regularly to determine if dose modifications or interruptions are indicated.